Name | Title | Contact Details |
---|
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.
Memphis Chemical and Janitorial Supply De(3B's LLC) is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
San Antonio Behavioral Healthcare Hospital is a trusted mental health treatment facility location in San Antonio, TX
Tapimmune Inc is a Issaquah, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.